​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​JOBS​​CALLS​​​​​​​​PR​ES​S​​​​​​RESTRICT​E​D AREA
EPIC

​​​​​​V3_logo-epic-medium (002).png



„Cancer inhibitors" in immune therapy: initiation of a promising research project

 

Cancer is characterized by uncontrolled cell growth, which can spread to otherwise healthy tissue and organs. Only five to ten percent of cancers are caused by inherited genetics, the majority of the cases are triggered by external factors such as tobacco consumption, diet, infections, or radiation. These external factors may induce so-called epigenetic changes, which may result in cancer cells being no longer recognized by the immune system. Cancer cells thus "hide" from the immune system.

However, some of these epigenetic changes are reversible, and that's where the scientists are going to act on. Utilizing inhibitory compounds (in short, inhibitors) allows prevention of these changes and reactivate previously deactivated genes, so that the immune system can retake action and remove degenerated cells.

The „Epigenetics of Immunity in Cancer" (EPIC) project was started in September 2019, focusing on histone deacetylase (HDAC) inhibitors. The research team comprises of chemists, clinicians, biologists, and bioinformaticians from the universities of Udine, Salzburg, and Trieste, as well as the Institute for Biomedicine at Eurac Research in Bolzano. The team is testing the effect of HDAC inhibitors in cancer cells and their suppressive role in tumor progression. In particular, the University of Udine is checking HDAC inhibition based on a library of HDAC compounds, whereas the University of Trieste is optimizing promising compounds with the aid of computer programs followed by their synthesis. At the University of Salzburg, selected inhibitors are being tested in cell models with respect to their influence on the immune system. Data generated by all partners are shared with bioinformaticians at Eurac Research, who are tasked with their analysis. Invoking next generation sequencing methods, the differences between cancer cells with and without inhibitors are measured: which genes are active, where are they active and what consequences could these compounds have in the human organism. Data obtained from theses analyses are compared to international databases in order to gain additional knowledge on cancer development. In this way, the three-year lasting project is supposed to create the basis for novel advances in cancer immune therapy.


This project is funded by the European Regional Development Fund and the Interreg V-A Italia-Österreich 2014-2020. ​

For more information​christian.weichenberger@eurac.edu



Useful links: 

https://www.keep.eu/project/23676/epigenetics-of-immunity-in-cancer

https://uni-salzburg.elsevierpure.com/de/projects/epigenetic-regulation-of-immunity-in-cancer

http://www.interreg.net/de/progettazione.asp

https://qui.uniud.it/notizieEventi/ricerca-e-innovazione/epic-la-ricerca-sul-cancro-ha-un-alleato-in-piu



​​​​​​​​​​​​​​​​​​​​​​​​​​​QUICK LINKS
AWARDS

 ​​​
  FOLLOW US​​


​​


​ 
CONTACT

Viale Druso, 1 / Drususallee 1
39100 Bolzano / Bozen - Italy
How to reach us​
Tel: +39 0471 055 055
Fax: +39 0471 055 099
Email: info@eurac.edu
PEC:administration@pec.eurac.edu​
Partita IVA: 01659400210
Pri​v​​​acy
Host of the Alpine Convention